Abstract
More than 50% of patients with clinical heart failure have a preserved ejection fraction. Despite mortality that is similar to or slightly lower than heart failure with reduced ejection fraction, trials to date have not shown a therapy that imparts a mortality benefit in heart failure with preserved ejection fraction (HFpEF). HFpEF represents a heterogeneous disorder with a complex pathophysiologic basis, and this may contribute to the negative results in clinical trials. Geographic variations in both patient selection and adherence to study medications confound the interpretation of the trial results. Mineralocorticoid receptor antagonists may be useful in selected patients.
Original language | English (US) |
---|---|
Pages (from-to) | 525-535 |
Number of pages | 11 |
Journal | Heart Failure Clinics |
Volume | 14 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2018 |
Keywords
- Aldosterone blocker
- Eplerenone
- Heart failure
- Heart failure with preserved ejection fraction
- Spironolactone
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine